Daniela Morales-Espinosa

1.3k total citations
25 papers, 534 citations indexed

About

Daniela Morales-Espinosa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Daniela Morales-Espinosa has authored 25 papers receiving a total of 534 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Daniela Morales-Espinosa's work include Lung Cancer Treatments and Mutations (13 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Daniela Morales-Espinosa is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Daniela Morales-Espinosa collaborates with scholars based in Spain, Mexico and United States. Daniela Morales-Espinosa's co-authors include Rafael Rosell, Niki Karachaliou, Santiago Viteri, Cristina Teixidó, María González‐Cao, Óscar Arrieta, Miguel Ángel Molina‐Vila, Julio Sotelo, María González Cao and Mónica Garzón and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and British Journal of Cancer.

In The Last Decade

Daniela Morales-Espinosa

23 papers receiving 524 citations

Peers

Daniela Morales-Espinosa
Greg Friberg United States
Takehisa Suzuki Japan
Irene De Santo Italy
Naixin Liang China
Xianglong Tian China
Caterina Mancarella Italy
Xinhai Wan United States
Adam R. Wolfe United States
Ceren Gönen Korkmaz Norway
Greg Friberg United States
Daniela Morales-Espinosa
Citations per year, relative to Daniela Morales-Espinosa Daniela Morales-Espinosa (= 1×) peers Greg Friberg

Countries citing papers authored by Daniela Morales-Espinosa

Since Specialization
Citations

This map shows the geographic impact of Daniela Morales-Espinosa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniela Morales-Espinosa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniela Morales-Espinosa more than expected).

Fields of papers citing papers by Daniela Morales-Espinosa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniela Morales-Espinosa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniela Morales-Espinosa. The network helps show where Daniela Morales-Espinosa may publish in the future.

Co-authorship network of co-authors of Daniela Morales-Espinosa

This figure shows the co-authorship network connecting the top 25 collaborators of Daniela Morales-Espinosa. A scholar is included among the top collaborators of Daniela Morales-Espinosa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniela Morales-Espinosa. Daniela Morales-Espinosa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Christenson, Eric S., Anthony B. El-Khoueiry, Andrés Cervantes, et al.. (2022). AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors: Phase 1/2a study design and rationale.. Journal of Clinical Oncology. 40(16_suppl). TPS2673–TPS2673. 5 indexed citations
3.
Malapelle, Umberto, Danilo Rocco, Mónica Garzón, et al.. (2017). Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. British Journal of Cancer. 116(6). 802–810. 95 indexed citations
4.
Karachaliou, Niki, Daniela Morales-Espinosa, J. Garde, et al.. (2017). P2.06-010 AZD9291 as 1st-Line Therapy for EGFR Mutant NSCLC Patients with Concomitant Pretreatment EGFR T790M Mutation. The AZENT Study. Journal of Thoracic Oncology. 12(1). S1074–S1075. 1 indexed citations
5.
Karachaliou, Niki, Guillermo Crespo, Erika Aldeguer, et al.. (2017). Interferon-gamma (INFG), an important marker of response to immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) and melanoma patients.. Journal of Clinical Oncology. 35(15_suppl). 11504–11504. 12 indexed citations
6.
Garzón, Mónica, Sergi Villatoro, Cristina Teixidó, et al.. (2016). KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients. Translational Lung Cancer Research. 5(5). 511–516. 16 indexed citations
7.
Aguado, Cristina, Ana Giménez‐Capitán, Niki Karachaliou, et al.. (2016). Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients. Translational Lung Cancer Research. 5(5). 525–531. 20 indexed citations
8.
Morales-Espinosa, Daniela, Miguel Ángel Molina‐Vila, Ana Giménez‐Capitán, et al.. (2016). CHK1 inhibition as a therapeutic approach in KRAS mutated and squamous cell carcinoma NSCLC patients.. Journal of Clinical Oncology. 34(15_suppl). 11581–11581. 1 indexed citations
9.
Morales-Espinosa, Daniela, et al.. (2016). Treatment for small cell lung cancer, where are we now?-a review.. PubMed. 5(1). 26–38. 114 indexed citations
10.
Lazzari, Chiara, Alberto Verlicchi, Αναστάσιος Γκουντάκος, et al.. (2016). Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma. Pulmonary Therapy. 2(1). 1–18. 2 indexed citations
11.
Morales-Espinosa, Daniela, et al.. (2015). Pharmacogenomics in the Treatment of Lung Cancer: an Update. Pharmacogenomics. 16(15). 1751–1760. 4 indexed citations
12.
Karachaliou, Niki, María González Cao, Cristina Teixidó, et al.. (2015). Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints.. SHILAP Revista de lepidopterología. 12(2). 79–86. 34 indexed citations
13.
Teixidó, Cristina, Niki Karachaliou, María González‐Cao, Daniela Morales-Espinosa, & Rafael Rosell. (2015). Assays for predicting and monitoring responses to lung cancer immunotherapy.. SHILAP Revista de lepidopterología. 12(2). 87–95. 32 indexed citations
14.
Karachaliou, Niki, Rafael Rosell, Daniela Morales-Espinosa, & Santiago Viteri. (2014). Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. Expert Review of Anticancer Therapy. 14(7). 807–815. 30 indexed citations
15.
Morales-Espinosa, Daniela, David Cantú de León, Dan Green, et al.. (2013). Characterization of DNA methylation of the promoters CTCF and BORIS (CTCFL) in breast and ovarian cancer.. Journal of Clinical Oncology. 31(15_suppl). e22151–e22151. 1 indexed citations
16.
Rosell, Rafael, Niki Karachaliou, Daniela Morales-Espinosa, et al.. (2013). Adaptive resistance to targeted therapies in cancer.. PubMed. 2(3). 152–9. 35 indexed citations
17.
Arrieta, Óscar, Benjamín Pineda, Norma Hernández‐Pedro, et al.. (2008). Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis. British Journal of Cancer. 99(1). 160–166. 60 indexed citations
18.
Rodríguez, Óscar Gerardo Arrieta, Luis Manuel Martínez-Barrera, Patricia Castillo, et al.. (2007). Wood-smoke exposure as a survival predictor in non-small cell lung cancer with response to erlotinib: An open label phase II study. Journal of Clinical Oncology. 25(18_suppl). 18029–18029.
19.
Tena‐Suck, Martha Lilia, et al.. (2006). Clinico-pathological and immunohistochemical characteristics associated to recurrence/regrowth of craniopharyngiomas. Clinical Neurology and Neurosurgery. 108(7). 661–669. 34 indexed citations
20.
Gamboa‐Domínguez, Armando, et al.. (2006). Response of negative estrogen-receptor hepatocarcinoma to tamoxifen, and survival of non-resectable patients. Annals of Hepatology. 5(4). 263–267. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Greg Friberg Breakdown of academic impact, for papers by Takehisa Suzuki Breakdown of academic impact, for papers by Irene De Santo Breakdown of academic impact, for papers by Naixin Liang Breakdown of academic impact, for papers by Xianglong Tian Breakdown of academic impact, for papers by Caterina Mancarella Breakdown of academic impact, for papers by Xinhai Wan Breakdown of academic impact, for papers by Adam R. Wolfe Breakdown of academic impact, for papers by Ceren Gönen Korkmaz
Rankless by CCL
2026